2026-04-18T06:04:51Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1242782025-12-05T12:08:57Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT
author
Cerio, Rino
author
Dirschka, Thomas
author
Dréno, Brigitte
author
Figueras Nart, Ignasi
author
Lear, John T.
author
Pellacani, Giovanni
author
Peris, Ketty
author
Ruiz de Casas, Andrés
2018-09-05T07:57:46Z2018-09-05T07:57:46Z2017-09-012018-07-24T12:01:41Z
Actinic keratosis (AK) is a chronic, progressive disease
of the skin that has undergone long-term sun exposure.
The affected areas contain visible and subclinical nonvisible
sun damage resulting in epidermal keratinocyte
dysplasia, known by many as ‘field cancerisation’ (1),
which is prone to AKs and sun-related skin cancer (2).
Thus, visible AKs are clinical biomarkers for a photo-damaged
field with subclinical damage associated with the
unpredictable risk of progression to invasive squamous
cell carcinoma (iSCC) (3). The aim of this multiexpert
opinion article is to provide a discussion succinctly
highlighting the clinical gaps for optimal management of
AK: the lack of a universal definition and the need for a
standardised grade assessment of AK/field cancerisation
that also takes into account individual risk.
cc by-nc (c) Acta Dermato-Venereologica, 2017 http://creativecommons.org/licenses/by-nc/3.0/es/ info:eu-repo/semantics/openAccess
Tumors
Malalties de la pell
Skin diseases
Actinic Keratosis, a Chronic, Progressive Disease: Understanding Clinical Gaps to Optimise Patient Management
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion